Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

29.4%

5 terminated/withdrawn out of 17 trials

Success Rate

70.6%

-15.9% vs industry average

Late-Stage Pipeline

12%

2 trials in Phase 3/4

Results Transparency

92%

11 of 12 completed trials have results

Key Signals

11 with results

Enrollment Performance

Analytics

Phase 2
11(64.7%)
Phase 1
4(23.5%)
Phase 3
2(11.8%)
17Total
Phase 2(11)
Phase 1(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT04043455Phase 2Terminated

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Role: lead

NCT03996369Phase 3Completed

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Role: lead

NCT03945188Phase 3Completed

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Role: lead

NCT04162769Phase 2Completed

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT00619931Phase 1Completed

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

Role: lead

NCT03155932Phase 2Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Role: lead

NCT02536404Phase 2Completed

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Role: lead

NCT03155945Phase 2Completed

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

Role: lead

NCT03072953Phase 2Terminated

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Role: lead

NCT04655599Phase 1Terminated

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

Role: lead

NCT02447302Phase 2Completed

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Role: lead

NCT03139032Phase 2Terminated

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Role: lead

NCT00664664Phase 2Completed

Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia

Role: lead

NCT02044874Phase 2Completed

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Role: lead

NCT01093508Phase 1Completed

Single-dose Safety Study of APD916 in Healthy Volunteers

Role: lead

NCT00529646Phase 1Completed

Single-Dose Safety Study of APD791 in Healthy Volunteers

Role: lead

NCT00452179Phase 2Completed

Safety and Efficacy Study of APD125 in Patient With Insomnia

Role: lead

All 17 trials loaded